InvestorsHub Logo
Followers 16
Posts 1354
Boards Moderated 0
Alias Born 05/11/2014

Re: guardiangel post# 29409

Saturday, 06/06/2015 11:17:19 AM

Saturday, June 06, 2015 11:17:19 AM

Post# of 30046
CMS decides the pricing of screening tests . . .

if and when either company submits a full PMA to the FDA and gets approval, then CMS will review and price the tests . . . the problem with GCDx's test is it is a LDT, and CMS will not review it . . . provista doesn't have a LC test in their pipeline yet, so they have years to go . . . so does EXAS, but with the EXAS CC test raking in millions per month, they have the cash flow to develop and submit a PMA . . .

no one will pay 99.- for a LDT . . . ask WG . . . the govt and the HC companies will pay whatever CMS recommends, NO OUT OF POCKET COSTS to the patient . . . this is key . . .

i'm trying to pick the pocket of the big guys, while they're too busy robbing the bank to notice . . . long only . . .

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.